Contacts
1 626 345 8596
Call 1 626 345 8596
Proteomics.
Done differently.

The only platform in the world to perform full spectrum protein analysis for drug and biomarker discovery.

We are Proteas.
A next-generation proteomics contract research organization.

Hitting a dead-end in your research with genomics and transcriptomics?

Get ahead of others. Discover Proteomics.

Using our globally patented mass spectrometry-based platforms, we offer high-end untargeted and targeted protein analysis services for cells | tissue | blood from pre-clinical and clinical studies.

We can help you accelerate:
  • Drug development with
    •   novel drug target identification
    •   assessment of drug safety and efficacy
  • Blood assay development for
    •   companion diagnostics | personalized treatment of disease
    •   early diagnosis | prognosis of disease

Drug Discovery Proteomics Platform

promina
Tissue biopsies from patients or animal models | Cells from in vitro studies
Proteomic analysis using nanotechnology enhanced mass spectrometry
Computational pipeline using machine learning and artificial intelligence
Novel Drug Target Discovery
In silico Protein Drug Network Analysis

We have completed

0 + studies

Biomarker Discovery | Assay Development Proteomics Platform

pronea
Clinical plasma samples
Proteomic analysis using nanotechnology enhanced mass spectrometry
Computational platform using machine learning algorithms
Biomarker Panel Discovery Targeted Assay Development
Assay Transferred to External Lab Adopted to existing mass spec On-site training
Assay Outsourced to Proteas Lab Fixed price per sample Guaranteed turnaround time
Assay Transferred to External Lab Adopted to existing mass spec On-site training
Assay Outsourced to Proteas Lab Fixed price per sample Guaranteed turnaround time

We have developed a ground-breaking assay for the early detection of heart disease

HeartBiT™️ Endorsed by Top Cardiologists

The unique aspect of the HeartBiT™️ blood test is its ability to holistically monitor multiple molecular processes that participate in the initiation and progression of heart disease with a single assay. Furthermore, the HeartBiT ™️, thanks to this unique capability, can provide a more precision medicine guidance to allow a cardiologist to implement an individualized and thus more effective approach in treating patients. Our on-going collaboration is intended, in part, to further validate and substantiate Proteas’ HeartBiT ™️ plasma fluid assessment.
Matthew Budoff, MD
Professor of Medicine, David Geffen School of Medicine at UCLA Program Director and Director of Cardiac CT, Division of Cardiology, Harbor-UCLA Medical Center

Unleashing the potential of next generation Proteomics for drug discovery and precision medicine

What sets us apart from other proteomic companies

  • Patented plasma isolation kit | instantly sterilizes and preserves sample at room temperature
  • Full chain of custody | barcoded samples
  • Minimal sample processing | no pre-analytical bias
  • Direct protein analysis | no proxies
  • Full spectrum protein analysis | no high-abundant protein depletion
  • Absolute analytical confidence using nanotechnology enhanced mass spectrometry
  • In-house developed machine learning algorithms

Testimonials

Proteas provided exceptional results on the proteomic profiling of brain tumors. Their patented platform is geared towards early diagnosis and personalized treatment of disease and has great potential in changing medical practice as we know it today. Proteas’ founders, Spiro and Antigoni are global proteomics experts with unparalleled know-how and scientific curiosity. Working with them has been a pleasure.

Josh Neman-EbrahimPhD Associate Professor

A lack of clinical tools that enable identification of high-risk pre-malignant multiple myeloma patients means that the current clinical approach is to only treat these patients when they develop active myeloma. Our collaboration with Dr. Garbis and Dr. Manousopoulou at Proteas has made significant progress in the development of novel blood biomarkers that are predictive of the progression from pre-malignant to active myeloma.

Andrew ZannettinoMD Pro Vice-Chancellor

I’ve had the pleasure to work and author articles with Dr. Garbis and Dr. Manousopoulou (a former student of mine) over the years. This work involved using the Plasma Proteomics Technology developed by Dr. Garbis at Proteas. The analytical rigor of this technology stands to transform our understanding of how chronic stress affects human physiology and pathophysiology.

George P. ChrousosMD UNESCO Chair on Adolescent Health Care

My team and I have had the distinct pleasure to collaborate with Proteas over this past year on multiple studies in the field of neurodegenerative disorders. Thanks to the outstanding proteomics and phosphoproteomics analysis performed by Proteas to a variety of biological specimens we obtained a more in-depth understanding the role of synaptic proteins in complex brain disorders. I have had nothing but positive experience working with Dr. Manousopoulou and Dr. Garbis at Proteas and recommend their work without any reservation.

Marcelo P. CobaPhD Associate Professor

Working with the founders of Proteas is an absolute joy. They are super-smart, exceptionally creative, and extraordinarily thorough. They will work closely with you to understand what you’re doing and what you’re trying to figure out, then help design the best and most efficient experiment to get you the answer. They will make whatever project you bring them better.

Leo D. WangMD PhD Associate Professor

I worked with Proteas on the proteomic profiling of HIV infected cells, both for single cell analysis and bulk cell analysis. They can work with minimal protein amounts and provide outstanding results and extensive follow-up support for manuscript and grant submission. We have a active, on-going collaboration and have submitted multiple NIH grants together. The founders of Proteas are amazing scientists and global leaders in the field of proteomics. Working with Proteas was an excellent experience and I highly recommend them.

Nadia Beliakova-BethellPhD Associate Professor